Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To examine the safety and efficacy of Z-338 (YM443) after long-term administration in patients with functional dyspepsia, and also to examine the pattern of long-term administration.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| YM443 | Drug | oral |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Subject's global assessment | Every week |
| Measure | Description | Time Frame |
|---|---|---|
| Disappearance rate of symptoms | Every week | |
| Laboratory tests, resting | At 0, 4, 12, 24, 36, 48 week | |
| 12-lead ECG |
Not provided
Inclusion Criteria:
Patient showing at least one of the following 4 symptoms from more than 6 months before obtaining consent
Patient showing at least 2 of the 8 symptoms shown below repeatedly from 3 months before obtaining consent (At least one symptom of either postprandial fullness or early satiation should be included.)
Patient showing either postprandial fullness, bloating in the upper abdomen, or early satiation as the major complaint among the 8 symptoms shown below at the time of obtaining consent
Outpatient
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Central Contact | Astellas Pharma Inc | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hokkaido | Japan | |||||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21934307 | Background | Matsueda K, Hongo M, Ushijima S, Akiho H. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration. Digestion. 2011;84(4):261-8. doi: 10.1159/000332404. Epub 2011 Sep 21. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D004415 | Dyspepsia |
| D012817 | Signs and Symptoms, Digestive |
| ID | Term |
|---|---|
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C410959 | Z 338 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| At 0, 24 and 48 week |
| Adverse events | During treatment |
| Kansai |
| Japan |
| Kantou | Japan |
| Kyushu | Japan |